Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell-derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“36) (54), all samples were aligned to the hg38 build (GRCh38.”
BackgroundThe Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
Methodfastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721 · cited 1×
“fastp (47) and aligned to the hg38 build (GRCh38.”
BackgroundfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
MethodRSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143 · cited 2×
“Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report.”
MethodUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Cells with TDP-43 pathology feature a redistribution of TDP-43 from the nucleus to the cytoplasm, where TDP-43 is ubiquitinated, hyperphosphorylated, and cleaved into C-terminal fragments (14).”
BackgroundThe GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547 · cited 3×
“the criteria of the Genotype Tissue Expression Consortium (64).”
BackgroundSelf-citation
Cited by
Items 101–200 of 239
Peters, O. M., & Brown, R. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00026-5 · Cited by 12
Divergent TDP43-regulated and TDP43-independent cryptic splicing in the cortex and spinal cord
Newton, D. F., Yang, R., Gutierrez, J., Hofmann, J. W., Chalasani, S., Yeh, F. L., Biever, A., & Friedman, B. A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00013-w · Cited by 14
“Probes for 67 cryptic splice variants were designed using Primer3 (Online Resource 22) [55], and synthesized by Integrated DNA Technologies.”
What Is the Role of Stathmin-2 in Axonal Biology and Degeneration?
Benarroch, E. E. (2021) · Neurology · doi:10.1212/wnl.0000000000012419 · Cited by 12
“A recent study showed that truncated STMN2 is also a marker of TDP-43 pathology in patients with FTD.(16) Truncated STMN2 accumulated in human iPSC-derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein.”
BackgroundInfluentialRamic, M., Andrade, N. S., Rybin, M. J., Esanov, R., Wahlestedt, C., Benatar, M. G., & Zeier, Z. R. (2021) · Brain Sciences · doi:10.3390/brainsci11111543 · Cited by 12
“Rather, DPRs likely disrupt mRNA metabolism through the dysregulation of RNA binding proteins, such as TDP-43, NPM1, and hnRNPA3 that facilitate mRNA transport and are closely linked to ALS pathobiology [20,22,30,77,78].”
BackgroundAberrant protein aggregation in amyotrophic lateral sclerosis
Wang, H., & Zeng, R. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12485-z · Cited by 12
“STMN2 cryptic exon inclusion resulting from mutation containing a stop codon and polyadenylation site after exon 1 was detected in ALS-FTD patients’ brains and spinal cords where TDP-43 pathology is present [228, 229].”
CHMP2B promotes CHMP7 mediated nuclear pore complex injury in sporadic ALS
Keeley, O., Mendoza, E., Menon, D., & Coyne, A. N. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01916-7 · Cited by 11
Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration
Glass, J. D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142854 · Cited by 12
Fu, X., He, Y., Xie, Y., & Lu, Z. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1113216 · Cited by 12
“Functional enrichment analysis based on cases that significantly associated with hub FIRGs in ALS To detect the most significantly influenced function in ALS pathogenesis by 15 hub FIRGs, we clustered all ALS samples from GSE153960 and GSE174332 into three groups by K-means clustering using an expression matrix of 15…”
MethodUdine, E., DeJesus‐Hernandez, M., Tian, S., das Neves, S. P., Crook, R., Finch, N. A., Baker, M., Pottier, C. P., Graff‐Radford, N. R., Boeve, B. F., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02720-2 · Cited by 12
“This has been observed in patient tissue, allowing STMN2 to serve as a marker for this pathology [41, 56, 68].”
Self-citationAbnormal Splicing Events due to Loss of Nuclear Function of TDP-43: Pathophysiology and Perspectives
Koike, Y. M. (2024) · JMA Journal · doi:10.31662/jmaj.2024-0038 · Cited by 14
“Of interest, truncated STMN2 levels correlate with phosphorylated TDP-43 protein levels (11) .”
BackgroundPagliari, E., Taiana, M. M., Manzini, P., Sali, L., Quetti, L., Bertolasi, L., Oldoni, S., Melzi, V., Comi, G. P., Corti, S. P., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05550-3 · Cited by 12
Altered mRNA transport and local translation in i3Neurons with RNA-binding protein knockdown
Dargan, R., Mikheenko, A., Johnson, N. L., Packer, B., Li, Z., Craig, E. J., Como, C. N., Sarbanes, S. L., Bereda, C., Hao, Y., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf709 · Cited by 16
Self-citationShao, M., Wang, L., Zhang, Q., Wang, T., & Wang, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00568-w · Cited by 18
“STMN2 was also overexpressed in hepatocellular, 357 neuroblastoma and ovarian cancer [11-13], which was associated with 358 advanced clinical characters and bad prognosis in hepatocellular cancer [11].”
BackgroundBridel, C., van Gils, J. H. M., Miedema, S. S. M., Hoozemans, J. J. M., Pijnenburg, Y. A. L., Smit, A. B., Rozemüller, A. J. M., Abeln, S., & Teunissen, C. E. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01200-1 · Cited by 9
“While progress has been made in the pathological characterization of FTLD, there is still limited insight into the molecular mechanisms leading to tau or TDP-43 pathology in the FTLD brain [6].”
BackgroundInfluentialElsadany, M., Elghaish, R. A., Khalil, A. S., Ahmed, A. S., Mansour, R. H., Badr, E., & Elserafy, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.749792 · Cited by 11
“All the data set transcriptomes are obtained from postmortem cortex samples by the NYGC ALS Consortium (Tam et al., 2019).”
MethodPhysiological regulation of neuronal Wnt activity is essential for TDP-43 localization and function
Zhang, N., Westerhaus, A., Wilson, M. M., Wang, E., Goff, L. A., & Sockanathan, S. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00156-8 · Cited by 14
“In this model, overall levels and distribution of TDP-43 are unchanged but TDP-43 molecular dysfunction is recapitulated by the reduction of speci fi c TDP-43 target gene mRNAs by day 46 of culture (Coyne et al, 2021; Klim et al, 2019; Ma et al, 2022; Melamed et al, 2019; Prudencio et al, 2020).”
Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
Ito, D., & Okada, K. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52234 · Cited by 10
Large-scale RNA-Seq mining reveals ciclopirox olamine induces TDP-43 cryptic exons
Sinha, I. R., Sandal, P. S., Spence, H., Burns, G. D., Mallika, A. P., Abbasinejad, F., Irwin, K. E., Cruz, A. L., Wang, V., Marx, S. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62004-5 · Cited by 19
Hipke, K., Pitter, B., Hruscha, A., van Bebber, F., Modic, M., Bansal, V., Lewandowski, S. A., Orozco, D., Edbauer, D., Bonn, S., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1169962 · Cited by 10
“Several features of TDP-43 loss-of-function, such as splice alterations of STATHMIN2 (Melamed et al., 2019; Prudencio et al., 2020), UNC13A (Brown et al.”
BackgroundMolecular Visualization of Neuronal TDP43 Pathology In SituPreprint
Erwin, A. L., Fernandez, M. G., Chang, M. L., Attili, D., Bekier, M., Pinarbasi, E. S., Russ, J. E., Sutanto, R., Thomas, D., Shen, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608477 · Cited by 10
“Brains from individual pups in each litter were pooled to maximize cell counts prior to plating; as a result, primary cortical neurons used for all studies include an even mix of cells from both male and female pups.”
Inhibition of nonsense-mediated decay in TDP-43 deficient neurons reveals novel cryptic exonsPreprint
Sinha, I. R., Ye, Y., Li, Y., Sandal, P. S., Wong, P. C., Sun, S., & Ling, J. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.28.661837 · Cited by 13
Faura, J., Heeman, B., Pottier, C. P., Baker, M., DeJesus‐Hernandez, M., Küçükali, F., Heiß, L., Wynants, S., den Broeck, M. V., Rijk, P. D., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02901-7 · Cited by 10
“STMN2 encodes an axonal protein that has been extensively studied in the field of TDP-43 proteinopathies [9, 47, 61], while ARHGAP32 , despite being identified in several studies, had not been highlighted for its relevance to the cryptic exon in this gene.”
InfluentialSelf-citationSmith, D. M., Aggarwal, G., Niehoff, M. L., Jones, S. A., Banerjee, S., Farr, S. A., & Nguyen, A. D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04190-9 · Cited by 13
“We therefore measured levels of several mRNAs known to be regulated by TDP-43, including Stathmin-2 (STMN2) and Unc-13 homolog A (UNC13A); total levels of these mRNAs are decreased by TDP-43 depletion [55–58].”
Smeyers, J., Osés-Prieto, J. A., Yadanar, L., Wang, M., Iadarola, M., Lu, S. H.-A., Wang, K. S., Watanabe, T. H., Debnath, J., Burlingame, A. L., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116494 · Cited by 8
“There was no detectable induction of the STMN2 cryptic exon, which is a sensitive readout for loss of TDP-43 nuclear function in neurodegeneration, 24,32,33 while STMN2 levels were unchanged across genotypes (Figure S3A).”
Karagianni, K., Dafou, D., Xanthopoulos, K., Sklaviadis, T., & Kanata, Ε. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00863-2 · Cited by 7
Neurodegeneration in human brain organoids infected with herpes simplex virus type 1Preprint
Rybak‐Wolf, A., Wyler, E., Legnini, I., Loewa, A., Glažar, P., Kim, S. J., Pentimalli, T. M., Oliveras, A., Beyersdorf, B. M., Woehler, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.434122 · Cited by 8
Large-scale RNA-seq mining reveals ciclopirox triggers TDP-43 cryptic exonsPreprint
Sinha, I. R., Sandal, P. S., Burns, G. D., Mallika, A. P., Irwin, K. E., Cruz, A. L., Wang, V., Rodríguez, J. L., Wong, P. C., & Ling, J. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.27.587011 · Cited by 7
C9ORF72 poly-PR disrupts expression of ALS/FTD-implicated STMN2 through SRSF7
Wang, K. S., Smeyers, J., Eggan, K. C., Budnik, B., & Mordes, D. A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01977-2 · Cited by 6
“The expression of the STMN2 cryptic exon clearly correlates with TDP-43 pathology in several neurodegenerative diseases [25, 30].”
InfluentialTanaka, Y., Sunamura, N., Kajitani, R., Ikeguchi, M., & Kunimoto, R. (2025) · Communications Biology · doi:10.1038/s42003-025-08463-4 · Cited by 6
“Given that the STMN2 cryptic exon has been proposed as biomarkers for ALS and FTD 13,52 , our fi ndings raise the possibility that the MNAT1 cryptic exon may similarly serve as a potential biomarker for neurodegenerative disorders associated with TDP-43 pro-teinopathy, such as ALS and FTD.”
Short structural variants as informative genetic markers for ALS disease risk and progression
Theunissen, F., Flynn, L. L., Anderton, R. S., & Akkari, P. A. (2022) · BMC Medicine · doi:10.1186/s12916-021-02206-y · Cited by 7
“This work points to a novel mechanism by which this SSV may regulate STMN2 gene expression and could further explain the recently elucidated STMN2 cryptic exon mechanism [44, 45] and its influence on neurodegenerative disease phenotype [47, 48].”
BackgroundTrautwig, A. N., Shantaraman, A., Chung, M., Dammer, E. B., Ping, L., Duong, D. M., Petrucelli, L., Ward, M. E., Glass, J. D., Nelson, P. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.30.656396 · Cited by 6
Self-citationJammal, J., Gómez, E. A., Al‐Chalabi, A., & Iacoangeli, A. (2026) · BMC Medicine · doi:10.1186/s12916-026-04725-y · Cited by 10
“For instance, Eshima et al. [10] validated their findings using an independent study provided by Prudencio et al. [40].”
DCPS modulates TDP-43-linked neurodegeneration through P-body-mediated RNA decay
Ye, Y., Zhang, Z., Xiao, Y., Zhu, C., Wright, N., Asbury, J., Huang, Y., Wang, W. J., Gómez-Isaza, L., Troncoso, J. C., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.01.018 · Cited by 10
Webber, C. J., Murphy, C. N., Rondón-Ortiz, A. N., van der Spek, S. J. F., Kelly, E. X., Lampl, N. M., Chiesa, G., Khalil, A. S., Emili, A., & Wolozin, B. L. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad122 · Cited by 5
Plessis‐Belair, J., Ravano, K., Han, E., Janniello, A., Molina, C., & Sher, R. B. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011411 · Cited by 7
“Reduced Stmn2 expression has been implicated in human TDP-43 pathologies in ALS and AD, as well as in Parkinson’s disease patients and FTLD-tau patients [62, 83–86].”
InfluentialMartin, E. J., Reyes, C., Mitevska, A., Santacruz, C., Alessandrini, F., Jones, I. E., Krishnan, G., Esteruelas, G., Gao, F., Finan, J. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.586073 · Cited by 5
“5I) To determine whether the prolonged mis-localization of TDP-43 induced by mild traumatic injury recapitulated aberrant RNA splicing, we employed qRT-PCR to quantify the level of cryptic exon inclusion in STMN2 [77, 78].”
TDP-43 Aggregate Seeding Impairs Autoregulation and Causes TDP-43 DysfunctionPreprint
Mamede, L. D., Hu, M., Titus, A. R., Vaquer‐Alicea, J., French, R. L., Diamond, M. I., Miller, T. M., & Ayala, Y. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.11.637743 · Cited by 6
“Several TDP-43 regulated genes are connected to essential neuronal function and their aberrant expression may underlie disease mechanisms (e.g., STMN2, UNC13A, KCNQ2 ) 9, 10, 11, 48, 49 .”
Mallika, A. P., Yu, J., Sitzman, O., Baghel, M. S., Renganathan, S., Sinha, I. R., Melnikova, T., Ling, J. P., & Wong, P. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.14.670400 · Cited by 5
Unlocking Disease‐Modifying Treatments for TDP‐43‐Mediated Neurodegeneration
Gil, R. S., & Walker, A. K. (2025) · BioEssays · doi:10.1002/bies.202400257 · Cited by 7
“Neuronal TDP-43 targets including STMN2 [67–69], UNC13A [70–73],and NPTX2 [74]show altered abundance in ALS/FTD, which strongly associate with dysfunctional axonogenesis, synaptic transmission, and neuro-toxicity, respectively, in human iPSC neuronal models.”
Magarotto, M., Gawne, R. T., Vilkaite, G., Beltrami, M., Mason, A. S., & Chen, H.-J. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf111 · Cited by 5
ALS-associated RNA-binding proteins promote UNC13A transcription through REST downregulation
Watanabe, Y., Suzuki, N., Nakagawa, T., Hosogane, M., Akiyama, T., Kageyama, N., Funayama, Y., Warita, H., Morimoto, S., Okano, H., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00506-0 · Cited by 6
“Despite prior evidence linking TDP-43 mislocalization to STMN2 downregulation (Prudencio et al., 2020, and others), no significant correlation was observed between their mRNA levels, reinforcing the inadequacy of gene expression correlation analyses for capturing ALS-specific RBP dysfunction (…”
Regulation of glypican 6-mediated Wnt activation maintains TDP-43 nuclear localization in neurons
Zhang, N., & Sockanathan, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-32069-9 · Cited by 7
Bharathi, V., Zeng, Y., Armour, E. M., Yue, M., Citrano, K., Lovchykova, A., Reeves, M. M., Rawlinson, B. D., Deture, M. A., Dunmore, J. A., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003573 · Cited by 5
“Transcript-level abundance was analyzed using nSolver 4.0 software (NanoString Technologies) and normalized to the endogenous control HTRP1, which was unaltered across disease subtypes [8].”
InfluentialSelf-citationMamede, L. D., Hu, M., Vaquer‐Alicea, J., Titus, A. R., dos Passos, P. M., Lantelme, E., French, R. L., Kirschner, P. A., Diamond, M. I., Miller, T. M., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003662 · Cited by 5
A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis
Pampalakis, G., Angelis, G., Zingkou, E., Vekrellis, K., & Sotiropoulou, G. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.657 · Cited by 6
“30 When administered at the onset of symptoms, it does not have any effect on lifespan or motor function of Tg-SOD1G93A, Tg-TDP43A315T and Tg-FUS(1-359) mouse models.”
BackgroundInfluentialInhibition of SOD1 trimerization is a novel drug target for ALS disease
Woo, T., Han, J., Kim, Y., Hwang, Y. J., Lee, M. G., Kang, S., Park, S., Ji, Y., Chung, Y., Baek, S., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00483-8 · Cited by 5
Tubulin regulates stability and localization of STMN2 by binding preferentially to its soluble form
Deng, X., Bradshaw, G. A., Kalocsay, M., & Mitchison, T. J. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202502192 · Cited by 6
Zhang, Z., van Olst, L., Alessandrini, F., Wright, M., Edwards, A. J., Boles, J. S., Nalbandian, A., Forsyth, A. V., Shepard, N., Watson, T. H., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02300-5 · Cited by 11
CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD
Pickles, S. R., Alepuz, D. Z., Koike, Y. M., Yue, M., Tong, J., Liu, P., Zhou, Y., Jansen‐West, K. R., Daughrity, L. M., Song, Y., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1251551 · Cited by 4
“However, as STMN2 RNA levels are also reduced in the frontal cortex of FTD patients (Prudencio et al., 2020), it is important to assess the contribution of STMN2 deficiency to FTDassociated phenotypes, in particular given the recent development of therapeutic strategies to rescue STMN2 splicing and restore STMN2 expre…”
BackgroundMethodResultInfluentialSelf-citationKoide, S., Ikegami, I., Hanyu, R., Koike, Y. M., Yamagishi, T., Toyama, G., Washida, A., Tada, M., Kakita, A., Onodera, O., et al. (2025) · FEBS Letters · doi:10.1002/1873-3468.70198 · Cited by 3
“Eleven reports positioned the forward primer almost entirely within the CE [10 – 20], two within exon 1 [32,33] and two upstream of exon 1 [34,35].”
Transcriptional Profiling of Hippocampus Identifies Network Alterations in Alzheimer’s Disease
Quarato, V., D’Antona, S., Battista, P., Zupo, R., Sardone, R., Castiglioni, I., Porro, D., Frasca, M., & Cava, C. (2022) · Applied Sciences · doi:10.3390/app12105035 · Cited by 3
Glia in FTLD-GRN: from supporting cast to leading role
Pinarbasi, E. S., & Barmada, S. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168215 · Cited by 3
ASO-enhancement of TARDBP exitron splicing mitigates TDP-43 proteinopathiesPreprint
Yamagishi, T., Koide, S., Toyama, G., Washida, A., Yamada, Y., Hanyu, R., Nadbitova, E., Koike, Y. M., Konno, T., Ishihara, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.22.604579 · Cited by 5
“2g), a key downstream target of TDP-43 23–25 .”
BackgroundInfluentialAltered mRNA transport and local translation in iNeurons with RNA binding protein knockdownPreprint
Dargan, R., Mikheenko, A., Johnson, N. L., Packer, B., Li, Z., Craig, E. J., Sarbanes, S. L., Bereda, C., Mehta, P. R., Keuss, M. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.26.615153 · Cited by 3
“Further, as expected for decreased TDP-43 levels, STMN2 mRNA levels are significantly reduced in both fractions (Figure 6A,C) (53).”
BackgroundSelf-citationTDP-43 pathology triggers SRRM4-dependent cryptic splicing of G3BP1 in ALS/FTDPreprint
Fakim, H., Ghosh, A., Amzallag, E., Danino, Y. M., Triassi, V., Brown, A., Pal, N., Deshaies, J.-E., Dubinski, A. F., Lacombe, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.17.676845 · Cited by 6
“Sample processing, library preparation, and RNA-seq quality control and alignment for the NYGC data have been described in previous papers [13, 71, 72].”
Self-citationLINE1 RNA dysregulation impairs chromatin accessibility in C9ORF72- and TDP-43-linked ALS/FTDPreprint
Li, Y., Dou, X., Xiao, Y., Zhang, Z., Ye, Y., Wright, N., Chang, K., Liu, C., Troncoso, J. C., He, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.30.679260 · Cited by 4
“…constitutively express the clustered regularly interspaced short palindromic repeat inactivation (CRISPRi) module 49 were transduced with lentivirus expressing either an sgRNA targeting TDP-43, or a non-targeting control sgRNA, and the stable iPSC lines were established as previously described 54 .”
Cryptic Splicing of GAP43 mRNA is a Novel Hallmark of TDP‐43‐Associated ALS and AD
Yang, M., Wang, Q., Kang, D., Wang, S., Jiang, Y., Wang, J., Chen, M., Liu, R., Gu, J., & Wang, X. (2025) · Advanced Science · doi:10.1002/advs.202412054 · Cited by 7
The Golgi apparatus: adaptations to neuronal shape and functions
Subkhangulova, A., & Mikhaylova, M. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00658-z · Cited by 7
“Microtubule-destabilizing protein stathmin-2 (STMN2), whose levels are decreased in the majority of ALS cases (Klim et al, 2019; Prudencio et al, 2020), was also implicated in the maintenance of Golgi structure (Strey et al, 2004; Bellouze et al, 2016).”
A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1
Yang, M., Wang, Q., Yan, R., Kang, D., Luo, W., Zhang, L., Liu, R., Wu, L., Gu, J., & Wang, X. (2026) · Nature Communications · doi:10.1038/s41467-026-68916-0 · Cited by 6
Trautwig, A. N., Shantaraman, A., Chung, M., Dammer, E. B., Ping, L., Duong, D. M., Watson, C. M., Petrucelli, L., Ward, M. E., Glass, J. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117142 · Cited by 10
Self-citationTDP-43: [GU]-ardian of the transcriptome
Sinha, I. R., Atkinson, A. L., Irwin, K. E., Ling, J. P., & Wong, P. C. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00944-2 · Cited by 2
“3) [32, 285, 286, 488, 489, 497, 515].”
Cheng, J., Wu, B., Liu, H., & Lin, W. (2025) · Scientific Reports · doi:10.1038/s41598-024-81315-z · Cited by 4
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Wang, P., Ajit, D., Nikolova, V. D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2200020/v1 · Cited by 3
A cryptic clue to neurodegeneration?
O’Brien, N. L., & Mizielinska, S. (2023) · Science · doi:10.1126/science.adg8501 · Cited by 2
RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Jiang, H., Wang, P., Ajit, D., et al. (2023) · eLife · doi:10.7554/elife.85921.2 · Cited by 2
Kozareva, V., Liu, Z., Blake, K. L., Qi, Y. A., Rollinson, S., Seddighi, S., Alsaidi, M., Tsitkov, S., Prudencio, M., Petrucelli, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.679403 · Cited by 2
“…datasets include bulk proteomics from frontal cortex of FTD brains 67 ; single - cell proteomics of ALS spinal - cord motor neurons stratified by TDP - 43 inclusion status 68 ; bulk RNAseq from FACS-sorted neuronal nuclei from frontal cortex of ALS-FTD cases 69 ; and bulk RNA - seq from a range…”
Self-citationO’Connor, J. T., Loo, H. Q., Guo, C., Pickles, S. R., Sundali, S., Jawahar, V. M., Dickson, D. W., Bloom, A. J., Petrucelli, L., Gitler, A. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689833 · Cited by 4
Self-citationBolger, I., Shaw, R., Tam, O. H., Roque, C. G., Jackson, C. A., O’Neill, K., Smith, C. M., Phatnani, H. P., Natarajan, K., & Hammell, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.09.698641 · Cited by 5
“In summary, the i3Neuron models recapitulate splicing alterations and gene/TE expression changes previously seen in cellular models of TDP-43 loss 9,20,41 , ALS-FTD cortical and spinal cord tissues 13,44,45 , as well as sorted ALS/FTD patient neurons 29 .”
Self-citationYu, H., Georgescu, C. H., Khorgade, A., Al‐Eryani, G., Bartlett, D. A., Brookhart, A., Koçkan, C., Webber, J. T., Shin, A., White, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.12.705617 · Cited by 6
Self-citationLuan, W., Gil, R. S., Martin, L. M. S., Cao, M. C., Vassallu, F., Venturato, J., West, P. K., Brown-Wright, H., Bademosi, A. T., Chye, Y. J., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02150-5 · Cited by 5
“In contrast , the Stmn2 gene that has previously shown alternative splicing in response to loss of TDP-43 [17, 20] was downregulated at onset (2 WOD) but normalised at recovery, without evidence of alternative splicing.”
Berge, K. V. D., Bakalar, D., Chou, H.-J., Kunda, D., Risso, D. S., Street, K., Purdom, E. A., Dudoit, S., Ngai, J., & Heavner, W. E. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102778 · Cited by 2
“…in each of the lineages: two of the top four genes in the neuronal lineage are implicated in neuron development and amyotrophic lateral sclerosis (Prudencio et al. 2020; Marques et al. 2020), while three of the top four genes in the Sus lineage are involved in oxidation-reduction, and two of the…”
Iacono, D., Murphy, E. K., Perl, D. P., & Day, R. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-36208-8 · Cited by 3
“Damage to the STMN2 gene has been linked to both sporadic and inherited forms of ALS and FTD 66,67 ; Ubiquitin, (1:2000, MCA-Ubi-1, Encor Biotechnology, Gainesville FL).”
Enhancer RNA-mediated transcriptional regulation of TDP-43 during early neural lineage specification
Jang, Y., Lee, H., Oh, M., Moon, J., Kim, S. S., Han, J., Park, J.-L., & Kim, S.-K. (2026) · Animal Cells and Systems · doi:10.1080/19768354.2026.2643998
“…1–2 kilobases in length and are closely associated with the transcriptional activation of specific genes (De Santa et al. 2010; Kim et al. 2019; Prudencio et al. 2020). eRNAs exert their regulatory effects by interacting with transcription factors, transcriptional coactivators, and RNA…”
Targeting TDP-43 in sporadic amyotrophic lateral sclerosis
Estevez‐Fraga, C., Álvarez‐Velasco, R., Afroz, T., Costa, M. R., Jovičić, A., Yeh, F. L., McColgan, P., Malaspina, A., & McCampbell, A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14023-5 · Cited by 1
Identification of Key Pathways and Genes in Dementia via Integrated Bioinformatics Analysis
Vastrad, B. M., & Vastrad, C. M. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01876-6 · Cited by 3
“In the current study, we downloaded expression profiling by high throughput sequencing dataset, GSE153960 [Prudencio et al. 2020], from the NCBI Gene Expression Omnibus database (NCBI GEO) (http://www.ncbi.nlm.nih.gov/geo/) [Clough and Barrett, 2016]), including gene expression data from 263 patients with dementia and…”
MethodInfluentialIdentification of Key Pathways and Genes in Dementia via Integrated Bioinformatics AnalysisPreprint
Vastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.18.440371 · Cited by 1
RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Wang, P., Ajit, D., Nikolova, V. D., et al. (2023) · eLife · doi:10.7554/elife.85921.1 · Cited by 1
Spence, H., Waldron, F. M., Saleeb, R. S., Brown, A., Rifai, O. M., Gilodi, M., Read, F. L., Roberts, K., Milne, G., Wilkinson, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563701 · Cited by 1
Self-citationPlessis‐Belair, J., Ravano, K., Han, E., Janniello, A., Molina, C., & Sher, R. B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.14.580338 · Cited by 1
Dykstra, M. M., Weskamp, K., Gómez, N., Waksmacki, J., Tank, E. M. H., Glineburg, M. R., Snyder, A. G., Pinarbasi, E. S., Bekier, M. E., Li, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.02.601776 · Cited by 1
Self-citationGomes, K. B. (2024) · Annals of Translational Medicine · doi:10.21037/atm-24-104 · Cited by 1
“It was demonstrated that truncated production of STMN2 transcripts is related to TDP-43 dysfunction, discerning FTLD-TDP from patients with FTLD-tau (28).”
Luan, W., Gil, R. S., Martin, L. M. S., Cao, M. C., Vassallu, F., Brown-Wright, H., Bademosi, A. T., Chye, Y. J., Wu, H. Y., Chang, M. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.04.641357 · Cited by 1
Statins and genetic inhibition of the mevalonate pathway activate an ATF3-STMN2 regenerative programPreprint
Nolan, M., Aryal, S., Ndayambaje, I. S., Cao, M., Lee, P., Hovde, M. J., Yun, S., Wlaschin, J. J., Held, A., Beaussant, H. D. A. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707492 · Cited by 2
Self-citationTauopathy primes co-filament assembly and dysfunction of TDP-43Preprint
Baghel, M. S., Burns, G. D., Mallika, A. P., Chen, X. K., Liu, F. L., Renganathan, S., Li, T., Troncoso, J. C., & Wong, P. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.11.723888 · Cited by 1
Analysis of STMN2 CA repeats in italian ALS patients shows no association
Doronzio, P. N., Lattante, S., Marangi, G., Martello, F., Conte, A., Bisogni, G., Bernardo, D., Patanella, A. K., Meleo, E., Zollino, M., et al. (2022) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2022.2102430 · Cited by 1
Mehta, A. R., McDade, K., Newton, J. L., Ruepp, M., Pal, S., Chandran, S., Smith, C., & Selvaraj, B. T. (2022) · medRxiv · doi:10.1101/2022.09.01.22279305
“Whilst truncated STMN2 positivity has recently been shown in human post-mortem tissue to be associated with an earlier age of onset in frontotemporal dementia (Prudencio et al., 2020), there had hitherto been no relationship with disease duration demonstrated in sALS.”
BackgroundSelf-citationRNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Wang, P., Ajit, D., Nikolova, V. D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2200020/v2
RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Wang, P., Ajit, D., Nikolova, V. D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2200020/v3
STMN2/NF-κB axis drives tumor growth in thyroid carcinomaPreprint
Liu, X., Zheng, J., Chen, X., Wang, C., Su, Z., Cai, S., & Chen, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3124413/v1
RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Jiang, H., Wang, P., Ajit, D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2200020/v4
RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathyPreprint
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Jiang, H., Wang, P., Ajit, D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2200020/v5
Eshima, J., Pennington, T. R., Choudhury, R., Garcia, J. M., Fricks, J., & Smith, B. S. (2024) · medRxiv · doi:10.1101/2024.03.21.24304538
ALS-associated RNA binding proteins converge on UNC13A transcription through regulation of RESTPreprint
Watanabe, Y., Suzuki, N., Nakagawa, T., Hosogane, M., Akiyama, T., Warita, H., Aoki, M., & Nakayama, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.619761
Unraveling temporal dynamics of the post-mortem transcriptome in amyotrophic lateral sclerosisPreprint
Shen, T., Spencer, B. E., Kuksa, P. P., Deerlin, V. M. V., Phatnani, H. P., Lee, E. B., & McMillan, C. T. (2025) · medRxiv · doi:10.1101/2025.06.10.25329061
“The Consortium’s bulk RNA-seq data processing was previously described 8,34,35 .”
Self-citationBridel, C., van Gils, J. H. M., Miedema, S. S. M., Hoozemans, J. J. M., Pijnenburg, Y. A. L., SMIT, A. B., Rozemüller, A. J. M., Abeln, S., & Teunissen, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26577173
Additional file 4 of Elevated nuclear TDP-43 induces constitutive exon skipping
Carmen‐Orozco, R. P., Tsao, W., Ye, Y., Sinha, I. R., Chang, K., Trinh, V., Chung, W., Bowden, K. D., Troncoso, J. C., Blackshaw, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26731618
Metadata
- Authors
- Prudencio, M., Humphrey, J., Pickles, S., Brown, A.-L., Hill, S. E., Kachergus, J. M., Shi, J., Heckman, M. G., Spiegel, M. R., Cook, C., Song, Y., Yue, M., Daughrity, L. M., Carlomagno, Y., Jansen-West, K., de Castro, C. F., DeTure, M., Koga, S., Wang, Y.-C., Sivakumar, P., Bodo, C., Candalija, A., Talbot, K., Selvaraj, B. T., Burr, K., Chandran, S., Newcombe, J., Lashley, T., Hubbard, I., Catalano, D., Kim, D., Propp, N., Fennessey, S., Fagegaltier, D., Phatnani, H., Secrier, M., Fisher, E. M. C., Oskarsson, B., van Blitterswijk, M., Rademakers, R., Graff-Radford, N. R., Boeve, B. F., Knopman, D. S., Petersen, R. C., Josephs, K. A., Thompson, E. A., Raj, T., Ward, M., Dickson, D. W., Gendron, T. F., Fratta, P., & Petrucelli, L.
- Affiliations
- Mayo Clinic (US)
- Icahn School of Medicine at Mount Sinai (US)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- New York Genome Center (US)
- University College London (GB)
- National Institutes of Health (US)
- Corresponding author
- Fratta, Pietro
- Petrucelli, Leonard
- ORCID
- Prudencio, Mercedes
- Humphrey, Jack
- Pickles, Sarah
- Brown, Anna-Leigh
- Hill, Sarah E.
- Shi, J.
- Heckman, Michael G.
- Spiegel, Matthew R.
- Cook, Casey
- Song, Yuping
- Daughrity, Lillian M.
- Carlomagno, Yari
- Jansen-West, Karen
- DeTure, Michael
- Koga, Shunsuke
- Wang, Ying-Chih
- Bodo, Cristian
- Candalija, Ana
- Talbot, Kevin
- Selvaraj, Bhuvaneish T.
- Chandran, Siddharthan
- Newcombe, Jia
- Lashley, Tammaryn
- Hubbard, Isabel
- Propp, Nadia
- Fennessey, Samantha
- Fagegaltier, Delphine
- Phatnani, Hemali
- Secrier, Maria
- Fisher, Elizabeth M.C.
- Oskarsson, Björn
- van Blitterswijk, Marka
- Rademakers, Rosa
- Boeve, Bradley F.
- Knopman, David S.
- Petersen, Ronald C.
- Josephs, Keith A.
- Thompson, E. Aubrey
- Raj, Towfique
- Ward, Michael
- Dickson, Dennis W.
- Gendron, Tania F.
- Fratta, Pietro
- Petrucelli, Leonard
- Venue
- Journal of Clinical Investigation
- Published
- 2020-10-19
- Volume
- 130
- Issue
- 11
- Pages
- 6080-6092
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7598060
- OpenAlex
- W3049616059
- Cited by
- 231
- References
- 68
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 48 · 2022: 30 · 2021: 19 · 2020: 2
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- NINDS and others, see below (see below)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- STMN2, TDP-43 pathology, frontotemporal dementia, FTLD-TDP, FTLD-tau, diagnostic biomarkers, iPSC-derived neurons, TARDBP mutations, phosphorylated TDP-43, age of disease onset, progressive supranuclear palsy, RNA expression
- MeSH terms
- DNA-Binding Proteins, Female, Frontal Lobe, Humans, Male, Middle Aged, Mutation, Biomarkers, Stathmin, Induced Pluripotent Stem Cells, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.